CYDY News and Press, CytoDyn Inc From 01/21/21

Palm Beach, FL – January 21, 2021 – Most of the news on advances for Covid-19 tend to focus on vaccines, however treatments are just as important. While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who al...

Correction to inclusion/exclusion criteria for eIND authorization VANCOUVER, Washington, Jan. 04, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab...

Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CytoDyn (CYDY) has announced that the FDA has accepted its amended protocol for adding an open-label extension to its Phase 3 trial (CD12) for Vyrologix™ (leronlimab-PRO 140) in severe-to-critically ill COVID-19.Last week, the company said it was on track to submit ...

Manuscript entitled: “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab,” by Nicholas J. Agresti, M.D. VANCOUVER, Washington, Dec. 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.Q...

The agency also provided specific guidance for inclusion/exclusion criteria for patients seeking leronlimab under eIND authorization VANCOUVER, Washington, Dec. 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-s...

VANCOUVER, Washington, Dec. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic i...

The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12 The CD12 trial completed enrollment with 394 patients on December 16 VANCOUVER, Washington, Dec. 24, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) ...

CytoDyn (CYDY) announces that a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND (eIND). In recent months, leronlimab has received more than 60 eIND authorizations from the FDA.FDA’s decision will enable the ...